Get started
Author

Clifford J. Whatcott

Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer
2015 · Clifford J. Whatcott, Caroline H. Diep, et al. · Clinical Cancer Research · 645
Targeting the Tumor Microenvironment in Cancer: Why Hyaluronidase Deserves a Second Look
2011 · Clifford J. Whatcott, Haiyong Han, et al. · Cancer Discovery · 223
PDF
Parallel Accumulation of Tumor Hyaluronan, Collagen, and Other Drivers of Tumor Progression
2018 · Xiaoming Li, H. Michael Shepard, et al. · Clinical Cancer Research · 99
Orchestrating the Tumor Microenvironment to Improve Survival for Patients With Pancreatic Cancer
2015 · Clifford J. Whatcott, Haiyong Han, et al. · The Cancer Journal · 97
Combined venetoclax and alvocidib in acute myeloid leukemia
2017 · James Bogenberger, Clifford Whatcott, et al. · Oncotarget · 95
PDF
Two small enzyme isoforms mediate mammalian mitochondrial poly(ADP-ribose) glycohydrolase (PARG) activity
2007 · Ralph G. Meyer, Mirella L. Meyer-Ficca, et al. · Experimental Cell Research · 84
Inhibition of ROCK1 kinase modulates both tumor cells and stromal fibroblasts in pancreatic cancer
2017 · Clifford J. Whatcott, Serina Ng, et al. · PLoS ONE · 79
PDF
Tumor-Stromal Interactions in Pancreatic Cancer
2012 · Clifford Whatcott, Haiyong Han, et al. · Critical Reviews™ in Oncogenesis · 77
Single-Cell Proteomic Profiling Identifies Combined AXL and JAK1 Inhibition as a Novel Therapeutic Strategy for Lung Cancer
2020 · Josephine A. Taverna, Chia-Nung Hung, et al. · Cancer Research · 64
Desmoplasia and chemoresistance in pancreatic cancer
2012 · Clifford J. Whatcott, Richard G. Posner, et al. · Europe PMC (PubMed Central) · 50
A specific isoform of poly(ADP-ribose) glycohydrolase is targeted to the mitochondrial matrix by a N-terminal mitochondrial targeting sequence
2009 · Clifford J. Whatcott, Mirella L. Meyer-Ficca, et al. · Experimental Cell Research · 39
TP-0903 is active in models of drug-resistant acute myeloid leukemia
2020 · Jae Yoon Jeon, Daelynn R. Buelow, et al. · JCI Insight · 34
PDF
TNK1 is a ubiquitin-binding and 14-3-3-regulated kinase that can be targeted to block tumor growth
2021 · Tsz-Yin Chan, Christina M. Egbert, et al. · Nature Communications · 31
PDF
Phenotypic chemical screening using zebrafish neural crest reporters identifies retinoid acid as an inhibitor of epithelial morphogenesis
2016 · Laura Jimenez, Jindong Wang, et al. · Disease Models & Mechanisms · 28
Abstract 5133: TP-1287, an oral prodrug of the cyclin-dependent kinase-9 inhibitor alvocidib
2017 · Wontak Kim, Hillary Haws, et al. · Cancer Research · 18
Abstract 235: AXL inhibition leads to a reversal of a mesenchymal phenotype sensitizing cancer cells to targeted agents and immuno-oncology therapies
2016 · Katherine K. Soh, Wontak Kim, et al. · Cancer Research · 10
ALK2 Inhibition Via TP-0184 Abrogates Inflammation-Induced Hepcidin Expression and Is a Potential Therapeutic for Anemia of Chronic Disease
2015 · Peter Peterson, Katherine K. Soh, et al. · Blood · 10
An alvocidib-containing regimen is highly effective in AML patients through a mechanism dependent on MCL1 expression and function.
2015 · B. Douglas Smith, Steven L Warner, et al. · Journal of Clinical Oncology · 10
A phase I, first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-1287 administered daily to patients with advanced solid tumors.
2020 · Ben George, Donald A. Richards, et al. · Journal of Clinical Oncology · 9
Phenotypic chemical screening using a zebrafish neural crest EMT reporter identifies retinoic acid as an inhibitor of epithelial morphogenesis
2016 · Laura Jimenez, Jindong Wang, et al. · Development · 9
A phase I, first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-3654 administered daily for 28 days to patients with advanced solid tumors.
2020 · Ignacio Garrido-Laguna, Patrick Michael Dillon, et al. · Journal of Clinical Oncology · 7
The PIM Kinase Inhibitor TP-3654 in Combination with Ruxolitinib Exhibits Marked Improvement of Myelofibrosis in Murine Models
2018 · Dipmoy Nath, Avik Dutta, et al. · Blood · 5
The ALK-2 Inhibitor, TP-0184, Demonstrates High Distribution to the Liver Contributing to Significant Preclinical Efficacy in Mouse Models of Anemia of Chronic Disease
2016 · Peter Peterson, Wontak Kim, et al. · Blood · 5
Abstract 606: Pkm2 activation modulates the tumor-immune microenvironment and enhances response to checkpoint inhibitors in preclinical solid tumor models
2021 · Salah Sommakia, Satya Pathi, et al. · Cancer Research · 4
TP-0184 Inhibits ALK2/ACVR1, Decreases Hepcidin Levels, and Demonstrates Activity in Preclinical Mouse Models of Functional Iron Deficiency
2017 · Peter Peterson, W K, et al. · Blood · 4
Works count: 94
Citation count: 1,773
H-index: 15
I10-index: 18
Year
Topic
Type